

Dedicated to making life better for people with rare and serious diseases

“Castle Creek Biosciences is a world class gene therapy company that is working to transform the lives of patients and the future of medicine.”

— **John Maslowski,**
Chief Executive Officer

Castle Creek Biosciences, Inc., a privately held company located in Exton, PA, is focused on developing and commercializing personalized gene therapies for patients with rare and serious genetic diseases. Castle Creek Biosciences is a portfolio company of Paragon Biosciences.

Novel Scientific Platform

There are too many newborns, young children, growing adolescents and others living with painful, debilitating rare and serious diseases with few or no treatment options. This poses an enormous challenge to patients and their families, but personalized gene therapies hold great promise to change their lives and rewrite the future.

Castle Creek Biosciences is leading the development of novel personalized gene therapies based on its proprietary technology and manufacturing platform to make safe and effective localized treatments for those who live with rare and serious diseases.

Clinical Development Pipeline

Castle Creek Biosciences is advancing clinical development programs in rare conditions including epidermolysis bullosa (EB). Patients living with EB have defective genes that result in very fragile skin that is prone to chronic blistering and wounds from normal friction or irritation. Symptoms often appear at or shortly after birth and persist throughout life.

There is no treatment approved by the U.S. Food & Drug Administration (FDA) for EB.

PRODUCT	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
FCX-007 (gene therapy) Recessive dystrophic epidermolysis bullosa	▶			
FCX-013 (gene therapy) Moderate-to-severe localized scleroderma	▶			
CCP-020 (topical ointment) Epidermolysis bullosa simplex	▶			



Follow us on Twitter @CastleCreekBio
and LinkedIn at [linkedin.com/company/castlecreekbio](https://www.linkedin.com/company/castlecreekbio)
and find us on Facebook at [facebook.com/Castle-Creek-Biosciences-115044166709915](https://www.facebook.com/Castle-Creek-Biosciences-115044166709915).



Castle Creek Biosciences' gene therapies are produced in its ~13,000 square foot cGMP manufacturing facility located at company headquarters in Exton, PA.

Working to bring major advances in care to patients in need

The company's lead gene therapy candidate, [FCX-007](#), is being evaluated in a Phase 3 clinical trial for the treatment of non-healing chronic wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), a severe and debilitating form of EB. The U.S. Food & Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT), orphan drug, rare pediatric disease and fast track designations for the development of FCX-007.

The company is also evaluating a diacerein topical ointment, [CCP-020](#), for the treatment of epidermolysis bullosa simplex (EBS) and potentially other forms of EB. CCP-020 has received fast track, rare pediatric disease and orphan drug designations from the FDA. In addition, the company is developing [FCX-013](#), a gene therapy for the treatment of moderate to severe localized scleroderma. The FDA has granted orphan drug, rare pediatric disease and fast track designations for FCX-013.

Investors

Castle Creek Biosciences is a portfolio company of Paragon Biosciences. Paragon is a life science innovator that invests in, builds, and advises bioscience companies. Paragon's mission is to serve patients living with severe medical conditions which do not yet have adequate treatments. Paragon's portfolio of independently-run bioscience companies focus on biopharmaceuticals, AI-enabled life science products, and advanced treatments such as cell and gene therapies.



Corporate Contact

Karen Casey
Castle Creek Biosciences, Inc.
(302) 750-4675

Media Contact

Adam Daley
Berry & Company Public Relations
(614) 580-2048



Follow us on Twitter @CastleCreekBio
and LinkedIn at [linkedin.com/company/castlecreekbio](https://www.linkedin.com/company/castlecreekbio)
and find us on Facebook at [facebook.com/Castle-Creek-Biosciences-115044166709915](https://www.facebook.com/Castle-Creek-Biosciences-115044166709915).

Executive Leadership Team

John Maslowski

Chief Executive Officer

Mary Spellman, MD, FAAD

Chief Medical Officer

Greg Wujek

Chief Commercial Officer

Babar Ghias

Chief Operating Officer

Sean Buckley

Chief Business Officer

"We believe our experience, expertise and proven processes provide us with the capability to deliver potentially transformative, localized therapies to these patients. We can make a difference."

— **Dr. Mary Spellman,**
Chief Medical Officer

Castle Creek Biosciences, Inc.

405 Eagleview Boulevard
Exton, PA 19341
castlecreekbio.com